Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 12, 2022

SELL
$3.74 - $10.66 $774,273 - $2.21 Million
-207,025 Closed
0 $0
Q1 2022

May 13, 2022

SELL
$7.81 - $20.45 $563,733 - $1.48 Million
-72,181 Reduced 25.85%
207,025 $1.97 Million
Q4 2021

Feb 11, 2022

BUY
$15.2 - $35.51 $73,522 - $171,761
4,837 Added 1.76%
279,206 $5.31 Million
Q3 2021

Nov 10, 2021

BUY
$21.78 - $40.45 $945,121 - $1.76 Million
43,394 Added 18.79%
274,369 $9.13 Million
Q2 2021

Aug 16, 2021

BUY
$32.5 - $48.96 $3.07 Million - $4.63 Million
94,514 Added 69.26%
230,975 $8.96 Million
Q1 2021

May 13, 2021

BUY
$41.61 - $54.3 $542,594 - $708,072
13,040 Added 10.57%
136,461 $6.58 Million
Q4 2020

Feb 16, 2021

SELL
$25.27 - $54.9 $693,737 - $1.51 Million
-27,453 Reduced 18.2%
123,421 $6.42 Million
Q3 2020

Nov 13, 2020

BUY
$18.49 - $27.24 $322,040 - $474,439
17,417 Added 13.05%
150,874 $4.04 Million
Q2 2020

Aug 14, 2020

BUY
$8.9 - $21.84 $228,026 - $559,562
25,621 Added 23.76%
133,457 $2.6 Million
Q1 2020

May 14, 2020

SELL
$7.14 - $15.99 $278,852 - $624,489
-39,055 Reduced 26.59%
107,836 $1.06 Million
Q4 2019

Feb 13, 2020

BUY
$5.1 - $11.2 $749,144 - $1.65 Million
146,891 New
146,891 $1.63 Million
Q4 2018

Feb 14, 2019

SELL
$3.44 - $5.76 $583,520 - $977,057
-169,628 Closed
0 $0
Q3 2018

Nov 13, 2018

BUY
$5.15 - $14.0 $73,727 - $200,424
14,316 Added 9.22%
169,628 $950,000
Q2 2018

Aug 13, 2018

SELL
$12.5 - $15.0 $11,237 - $13,485
-899 Reduced 0.58%
155,312 $2.04 Million
Q1 2018

May 14, 2018

BUY
$8.7 - $16.8 $158,609 - $306,280
18,231 Added 13.21%
156,211 $2.22 Million
Q4 2017

Feb 13, 2018

BUY
$7.35 - $12.3 $63,224 - $105,804
8,602 Added 6.65%
137,980 $1.13 Million
Q3 2017

Nov 13, 2017

BUY
$10.0 - $12.7 $45,300 - $57,531
4,530 Added 3.63%
129,378 $1.53 Million
Q2 2017

Aug 14, 2017

BUY
N/A
124,848
124,848 $1.26 Million

Others Institutions Holding TGTX

About TG THERAPEUTICS, INC.


  • Ticker TGTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 145,274,000
  • Market Cap $2.58B
  • Description
  • TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...
More about TGTX
Track This Portfolio

Track Allianz Asset Management Gmb H Portfolio

Follow Allianz Asset Management Gmb H and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Allianz Asset Management Gmb H, based on Form 13F filings with the SEC.

News

Stay updated on Allianz Asset Management Gmb H with notifications on news.